Harrow Reaffirms 2025 Revenue Guidance of $270–$280 Million

Reuters02-02
Harrow Reaffirms 2025 Revenue Guidance of $270–$280 Million

Harrow Inc. has reaffirmed its 2025 full-year revenue guidance of $270–$280 million, indicating another year of strong growth for the company. The guidance reflects continued positive demand trends across Harrow’s key revenue-driving products and meaningful progress within other areas of its portfolio. The company is also executing expansion plans, including doubling the sales force for VEVYE®, broadening the commercial footprint of IHEEZO® to office-based settings, and increasing the commercial presence of TRIESENCE® in surgical settings. These initiatives are driven by growing momentum and customer interest in Harrow’s products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646742) on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment